valid points but as the company aint willing to come forth and shed a little light on things. i see no other choice but to try and force there hand. im very pro sar even if it sounds like im not after my negative comments but im really at the end of my teather with it. ive been here ages so patience is not the issue ive just run out of it now
As if we understand TM reads this bb I think he will reflect deeply on this afternoon's postings:-
1. He doesn't need a mutiny of an EGM as this will as pointed out put any Pharma in a stronger position whether or not deal is on, continuing or the future - therefore, if there is and he can I am sure he would pass on the dialogue we all await.
2. I see both sides regarding NED , but, again do not see the point of EGM at this stage when a simple open letter to the BoD could quite easily get their take on the matter. I say this as if deal negotiations are current the BoD really don't need such distraction.
In conclusion, I believe some light will emerge over the next few weeks on CHK1 and lead us into Aurora/FLT3 era, whilst it is frustrating imo patience is the key GLA
I agree that any business especially micro caps with cash burn issues coupled with no income need to keep a really tight hold on costs.
I also agree that we're all in favour of ensuring that SAR keep there an eye on the ball & focus on the science, I'm not advocating we hire the Saatchi brothers to spin SAR, I would however, like some dialogue and communication. This wouldn't/ shouldn't cost much in £ or time.
Regular updates would bring SAR to a larger audience, and hopefully a higher share price. I'm obviously assuming that there's still news to be told.
A good post and value your alternative view and whilst accepting Rome wasn't built in a day we don't want to miss the boat holding out for a pipe dream.. If what we have has value surely there would be a queue at the door.. ?? The small management team was brought about as a cost cutting exercise to stay in business after their suspension I don't think it was by choice..
no. a lot of patience needed. takes years to move into the clinic, and deals can be done at any time over that period, (or not). But in the meantime the co improves the quality of supporting data and the molecules (steadily increasing value) for when a deal is done. I personally think ICR may take Chk1 into phase 1 itself (via the DDO mechanism). However they have recently moved into P1 on a collaboration with Astellas that started TEN years ago in preclinical. If we do think we have the best molecules and the most comprehensive patents, no point doing a deal unless the value fully reflects that. so Im unconcerned on timings and fluctuations in sp in the meantime. Part of the beauty of this is the low cash burn, and lack of spin. This is because they don't have a big management team, I wouldnt want that model to change.
Just your opinion.. CRT are only involved on Chk1 what about the other products.. No licensing deal in now almost 10 years of trading !! Don't you think its time the status quo was challenged?? It's getting a little tiresome being a mushroom.. ;+)
I'm with you. No disruption but simply trying to get SAR to bolster its top-team with wider managerial skills. If as we believe SAR could go to 5p+ in the future it would have a market cap of near £75M which to me would completely justify a wider skill set on the BOD.
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.